Company Overview and News
Q1 hedge fund letters, conference, scoops etc, Also read Lear Capital: Financial Products You Should Avoid?
Casual-dining chains have not been winners during this economic expansion. Millennials, with their need for more social media-worthy experiences, have been blamed for the decline.
BOSTON (Reuters) - Two days after billionaire investor William Ackman told clients that he was making money across all his funds again, he said on Thursday that his publicly traded Pershing Square Holdings Ltd portfolio was barely in the black so far this year.
Billionaire hedge-fund manager Bill Ackman on Thursday called for a breakup of United Technologies Corp. saying the individual businesses are more likely to trade at fair value as independent companies.
Stocks have seen a recovery for much of the week, but major equity indexes were all marginally lower on Thursday morning. The trend of endless buying the dips has not worked well lately, and many investors are wondering whether the best has been seen for 2018. Now all investors have to consider how they want their investments positioned for the longer term.
On May 16, John Staszak of Argus upgraded Chipotle Mexican Grill (CMG) from “hold” to “buy.” He increased Chipotle’s target price to $540. Staszak is optimistic about Brian Niccol’s leadership and expects the company’s SSSG and earnings to accelerate in the coming years. The initiatives that were taken by Chipotle’s management, like implementing digital advancements, menu innovations, expanding the catering and delivery services, and various marketing and promotional offerings, are expected to drive the company’s sales.
There is a lot of noise in the stock market. Every day, discrete events send stocks up and down. These discrete events can be company-specific, like earnings reports, murmurs about mergers and acquisitions, analyst upgrades and downgrades, or investor presentations. Those discrete events can also be macro-related, including economic data or geopolitical news.
The futures were slightly lower again Wednesday morning as traders tried to regroup from a sell-off on Tuesday that ended the Dow Jones industrial average’s eight-day winning streak. Rising interest rates were cited as the culprit, although they still are historically very low and probably headed higher.
The largest three 13F positions are Restaurant Brands International, Chipotle Mexican Grill, and Automatic Data Processing and together they account for around two-thirds of the portfolio.
Let’s be honest. We all innately know that stocks are valued not for where the company is, but for where it appears to be going. And since nobody has a crystal ball, it’s tacitly accepted that a stock’s price usually reflects the average risk — the unknown future — investors see in buying into a particular company.
With the 10-year Treasury yield eclipsing 3%, U.S. stock markets are under pressure Tuesday. The declines shouldn’t be too surprising though, as the market has been pretty hot over the past eight trading sessions. Here’s a look at our top stock trades for Wednesday.
After a nearly perfect 2017 that saw big gains happen alongside mitigated volatility, the stock market hasn’t been able to replicate that success in early 2018.
Chipotle Mexican Grill, Inc. (NYSE:CMG) shares are back in fashion. After last month’s earnings home run, momentum traders are salivating over the food stock, antsy to take a bite. The hope is that CMG will reclaim some of its former glory by continuing the newfound uptrend.
In the first quarter, Chipotle Mexican Grill (CMG) posted adjusted EPS (earnings per share) of $2.13 on revenue of $1.2 billion. Analysts were expecting the company to post EPS of $1.57 on revenue of $1.2 billion. The company also outperformed analysts’ SSSG (same-store sales growth) estimate of 1.3%, posting SSSG of 2.2%.
Chipotle Mexican Grill, Inc.’s (CMG - Free Report) increased focus on food safety, and various sales-building and strategic initiatives are major positives amid a tough economic environment characterized by high costs and stiff competition. Recently, the company reported first-quarter 2018 results, wherein earnings surpassed analysts’ expectations while revenues were in line with the same. Adjusted earnings of $2.
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...
as of ET